Neil Campling discusses the US government lifting foreign access restrictions on Anthropic's Fable 5 AI model after new security safeguards were added, framing it as a positive for Anthropic's AI leadership versus China. He notes that Anthropic's new science software could accelerate drug discovery, but the bigger competitive impact may be on Google's DeepMind, which now faces a catch-up challenge. A brief market mention of Schrodinger falling on the news draws no investable thesis.
- US lifts restrictions on Anthropic's Fable 5 AI model after added safeguards.
- Move seen as enabling Anthropic to keep pace with China's frontier AI models.
- Anthropic's new science software could speed drug discovery time-to-market.
- Google's DeepMind, formerly the leader in AI for science, now faces competitive pressure.
- Schrodinger stock fell on the news, but no trader thesis from speaker.